Global Vaccines (Monovalent, Multivalent) Market Research Report 2024-2028: $94.9 Billion Market Analysis by Technology, Disease, Route of Administration
June 05, 2024 04:25 ET
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease...
Global Anti-Venom Market Report 2024-2032, by Species, Anti-venom Type, Mode of Action, End User and Region - A $2 Billion Market by 2032
June 04, 2024 12:37 ET
|
Research and Markets
Dublin, June 04, 2024 (GLOBE NEWSWIRE) -- The "Global Anti-Venom Market Report by Species, Anti-venom Type, Mode of Action, End User, and Region 2024-2032" report has been added to ...
Allergy Vaccine Market Trends, Forecast and Competitive Analysis: A $3.6 Billion Market by 2030 with a CAGR of 7.5% from 2024 to 2030
May 31, 2024 04:18 ET
|
Research and Markets
Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Allergy Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global...
Meningococcal Vaccines Analysis Report 2024: A $3.1 Billion Market by 2024 - Simplifying Regulatory Procedures to Accelerate Vaccine R&D
May 29, 2024 04:14 ET
|
Research and Markets
Dublin, May 29, 2024 (GLOBE NEWSWIRE) -- The "Meningococcal Vaccines Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering.Meningococcal Vaccines Market will surpass...
Global Vaccine Delivery Devices Market Analysis & Forecast 2024-2034
May 27, 2024 04:01 ET
|
Research and Markets
Dublin, May 27, 2024 (GLOBE NEWSWIRE) -- The "Global Vaccine Delivery Devices Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering.The global...
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
May 14, 2024 16:00 ET
|
Dyadic International, Inc.
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant...
$1.6+ Billion Anti-Venom Markets - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F: Next-Generation Anti-Venoms & Precision Medicine Approaches
May 13, 2024 10:52 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Anti-Venom Market - Global Industry Size, Share, Trends, Opportunity & Forecast, 2019-2029F" report has been added to ResearchAndMarkets.com's...
Global Hepatitis B Vaccines Business Research Report 2024: Market to Reach $3.9 Billion by 2030 from $2.9 Billion in 2023 with Combination Vaccines Accounting for $2.6 Billion
May 13, 2024 09:58 ET
|
Research and Markets
Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "Hepatitis B Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Hepatitis B Vaccines Market...
Vaccines Market is Expected to Reach $94.9 billion | MarketsandMarkets™
May 10, 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, May 10, 2024 (GLOBE NEWSWIRE) -- Vaccines market in terms of revenue was estimated to be worth $78.0 billion in 2024 and is poised to reach $94.9 billion by 2029, growing at a CAGR of 4.0%...
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update
May 08, 2024 16:05 ET
|
Vaxcyte, Inc.
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout,...